Identification of Novel Predictive Biomarkers for Endometrial Malignancies: N-Acylethanolamines by Ayakannu, Thangesweran et al.
ORIGINAL RESEARCH
published: 11 June 2019
doi: 10.3389/fonc.2019.00430
Frontiers in Oncology | www.frontiersin.org 1 June 2019 | Volume 9 | Article 430
Edited by:
Jian-Jun Wei,










†These authors have contributed
equally to this work as joint last
authors
Specialty section:
This article was submitted to
Women’s Cancer,
a section of the journal
Frontiers in Oncology
Received: 01 February 2019
Accepted: 07 May 2019
Published: 11 June 2019
Citation:
Ayakannu T, Taylor AH, Marczylo TH,
Maccarrone M and Konje JC (2019)





Identification of Novel Predictive
Biomarkers for Endometrial
Malignancies: N-Acylethanolamines
Thangesweran Ayakannu 1,2, Anthony H. Taylor 1,3, Timothy H. Marczylo 1,4,
Mauro Maccarrone 5† and Justin C. Konje 1,6*†
1 Reproductive Sciences Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester,
United Kingdom, 2Gynaecology Oncology Cancer Centre, Liverpool Women’s NHS Foundation Trust, Liverpool Women’s
Hospital, Liverpool, United Kingdom, 3Department of Molecular and Cell Biology, University of Leicester, Leicester,
United Kingdom, 4 Toxicology Department at the Centre for Radiation, Chemical and Environmental Hazards, Public Health
England, Oxfordshire, United Kingdom, 5Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy,
6Department of Obstetrics and Gynaecology, Sidra Medicine, Women’s Wellness and Research Center, HMC, Doha, Qatar
Objective: To identify new biochemical markers for endometrial cancer (EC). Recent
evidence suggests that members of the endocannabinoid system (N-acylethanolamines)
that bind to and activate receptors that are dysregulated in EC are involved in this
tumour’s biology. These observations suggest increased N-acylethanolamine levels in
the tissue that might appear in plasma and could be used as disease biomarkers.
Methods:N-arachidonoylethanolamine (anandamide, AEA) and theN-acylethanolamine
substances, N-oleoylethanolamine (OEA), and N-palmitoylethanolamine (PEA) were
quantified in plasma and endometrial tissue collected from 31 EC and seven atrophic
controls using UHPLC-MS/MS. Receiver-operating characteristics (ROC) and logistic
regression were used to determine diagnostic accuracy. Cannabinoid receptor 1 (CB1)
and 2 (CB2) protein levels were determined by specific immunohistochemistry and
histomorphometric analyses. Correlations between plasma and tissue levels of the three
N-acylethanolamines and tissue levels of the three N-acylethanolamines and CB1 and
CB2 receptor expression levels were determined using correlation analysis.
Results: Plasma and tissue AEA and PEA levels were significantly (p < 0.05) higher in
EC than controls whilst OEA levels were significantly elevated in type 1 EC tissues but
not in plasma. There were significant positive correlations between plasma and tissue
levels of AEA (R2 = 0.302, p = 0.008) and PEA (R2 = 0.182, p = 0.047), but not for OEA
(R2 = 0.022, p = 0.506). The diagnostic accuracies for EC were: sensitivity of 53.3%,
specificity of 100% for plasma AEA (>1.36 nM); sensitivity of 73.3%, specificity of 100%
for plasma PEA (>27.5 nM); and sensitivity of 93.3%, specificity of 28.6% for plasma
OEA (>4.97 nM). Logistic regression increased the area under the ROC curve (AUC)
from 0.781 for AEA, 0.857 for PEA, and 0.543 for OEA to a combined AUC of 0.933
for EC diagnosis. Significant inverse correlations between tissue AEA (R2 =0.343, p =
0.003) and PEA (R2 = 0.384, p < 0.0001) levels and CB1 expression were observed.
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No correlation between tissue levels of OEA and CB1 and tissue levels of any of the three
N-acylethanolamines and CB2 protein expression were observed, except in the type 1
EC patients.
Conclusion: Since plasma AEA and PEA are significantly elevated in patients with EC
and a reflection of production by the endometrial tumour, then these lipids have the
potential to be useful biomarkers for the early diagnosis of EC.
Keywords: anandamide, biomarker, endocannabinoid, endometrial cancer, prediction
INTRODUCTION
Despite improvements in the overall survival rates of endometrial
cancer (EC), its incidence has risen by ∼40% and mortality
by 20% since 1999 (1–4). This disease is often diagnosed at
an early stage, but ∼20% of women present with advanced
disease. Worldwide, 320,000 new cases were diagnosed in 2012
(5) and in the USA, it is the most common gynaecological
malignancy, with over 50,000 new cases and almost 8,600
deaths reported each year (6). In the UK, it is the 4th
most common cancer in women (4) and because of an
ageing population and increasing obesity rates, its incidence is
rising rapidly.
Current methods for EC diagnosis rely primarily on
invasive techniques (biopsy) with current biochemical screening
methods being unreliable (7). Post-menopausal bleeding is
often the symptom whose investigation leads to diagnosis
in most cases, but for a significant number of women
this represents late presentation of disease. Furthermore, the
early detection of EC is hampered by the lack of validated
biomarkers (1, 5, 6). There is therefore a need for the
identification and evaluation of novel validated biomarkers
that are ideally linked to the biology of EC. Recently, a
relationship between the endocannabinoid system and other
forms of cancer has emerged (8–10). This system consists of
a family of signalling lipids called N-acylethanolamines (NAE),
of which the endocannabinoid N-arachidonoylethanolamine
(anandamide; AEA) and the endocannabinoid-like compounds,
N-oleoylethanolamine (OEA) and N-palmitoylethanolamine
(PEA), are the best characterised (10) with respect to their
receptors and the enzymes responsible for their synthesis
and degradation (11, 12). Where this relationship has been
investigated, it has provided an improved understanding of the
biology of various tumours (13, 14). Such a relationship with
ECs, however, remains relatively unexplored (8, 15). We have
recently shown that the expression of cannabinoid receptors 1
and 2 (CB1 and CB2, respectively) is reduced in endometrial
cancer tissue when compared to that of women of a similar age
without EC (16). We therefore hypothesised that the lack of
CB1 and CB2 protein in the endometrial cancer tissue might
result in compensatory local increases of tissue NAE levels and
that plasma concentrations of the NAEs might be a surrogate
marker of tissue levels (as the NAEs are released from the
tissue). Furthermore, we believe that an understanding of this
relationship might eventually provide potential novel biomarkers
and treatments for EC.
Here, we evaluate this relationship by quantifying levels of the
three NAEs, AEA, OEA, and PEA, in the endometria of women
with EC and normal controls and compare those levels to the
women’s plasma concentrations. We also compare the levels of
these NAEs with CB1 and CB2 proteins in the same patients.
From these data, we propose that plasma concentrations have
the potential to be surrogates for tissue NAE levels and therefore
possible good biochemical markers for EC.
MATERIALS AND METHODS
Study Population
Volunteers were women undergoing surgical treatment
(hysterectomy and bilateral salpingoophorectomy) for either
endometrial cancer (EC group) or benign conditions, such as
uterine prolapse (control group) at the University Hospitals
of Leicester National Health Service Trust. All women gave
signed written informed consent to take part in the study,
which was approved and conducted according to the guidelines
of the Leicestershire and Rutland Ethics Committee. The
exclusion criteria included being on hormonal treatment [e.g.,
hormone replacement therapy or the levonorgestrel intrauterine
system (Mirena R© Coil)], on prescription or recreational
drugs (including marijuana); suffering from chronic medical
conditions or any other form of cancer or a smoker. The
cancer volunteers (EC group) were categorised according to
the preliminary histology of the endometrial biopsies obtained
at standard hysteroscopy and confirmed after surgery. All of
the women in the EC group had stage 1 disease. The final
histopathological categorisation into type and grade was made
by the hospital Histopathology Department based on FIGO
criteria. Surgery was performed within 2 weeks of the diagnosis
in all cases.
Plasma Collection
Venous blood samples were obtained from the antecubital vein
into vacutainer tubes containing EDTA (Sarstedt, Leicester, UK).
Plasma was separated after centrifugation at 1200× g for 30min
at 4◦C within 60min of collection and immediately transferred
into 7mL Kimble scintillation vials (Kinesis, St. Neots, UK) and
stored as 2mL aliquots at−80◦C prior to plasma lipid extraction
and quantification.
Endometrial Tissue Collection
Following hysterectomy, fresh uteri were placed on ice,
transferred immediately to the Histopathology Department,
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where normal and tumour tissue biopsies were obtained by a
senior gynaecological oncology histopathology consultant and
fixed in 10% formalin for confirmation of the preliminary
histological diagnosis. Additional biopsies of normal and tumour
tissue were collected, washed (to remove blood) with sterile 1X
phosphate buffered saline (PBS) and placed in separate sterile
polypropylene tubes. These were then immediately transported
to the laboratory in liquid nitrogen and stored at −80◦C for
later lipid extraction and NAE quantification. Power analysis of
pilot data (17) indicated that to determine a 50% difference in
the means of the NAE measurements with α = 0.05 and β =
0.8, a minimum of 3, 5, and 4 clinical samples for AEA, OEA,
and PEA were required. Biopsies were collected until these limits
were exceeded.
Extraction and Quantification of the NAEs
NAE extraction from plasma was by a solid-phase extraction
(SPE) method (18, 19) and for tissues (normal and tumour)
by our modified SPE published method for solid tissues (20).
For plasma (0.5mL), deuterated AEA-d8 (2.5 pmol/mL), OEA-
d2 (2.5 pmol/mL), and PEA-d4 (5 pmol/mL) internal standards
(Cayman Chemical, Cambridge, UK) were added and then
diluted to 1mL with deionised water prior to loading onto an
Oasis HLB cartridge (Waters Ltd, Elstree, UK). For endometrial
tissues, AEA-d8 (12.5 pmol/g), OEA-d2 (12.5 pmol/g), and PEA-
d4 (25 pmol/g) and 1mL phosphoric acid (5% v/v) were added
to ∼100mg of tissue. This mixture was then diluted with 1mL
deionised water, homogenised using a TissueRuptor (QIAGEN,
Manchester, UK), and centrifuged at 1500 × g for 30min at
4◦C. The supernatant was transferred to a fresh tube and then
loaded onto preconditioned Oasis HLB cartridge for the lipid
extraction (as for plasma). After washing twice, lipids were
eluted into acetonitrile, evaporated to dryness under a gentle
stream of nitrogen, and re-suspended in acetonitrile (80 µL)
ready for analysis. Duplicate 0.5mL aliquots were processed and
each extract analysed in triplicate. The quantification of NAEs
was performed on an ultra-HPLC-tandem mass spectrometry
(UHPLC-MS/MS) system, consisting of an Acquity ultra-HPLC
system in line with a Quattro Premier tandemmass spectrometer
(Waters Corp, Milford, Massachusetts, USA). The finer points of
UHPLC-MS/MS gradient conditions and transitions used have
been reported previously (18–20).
Measurement of CB1 and CB2
Protein Levels
CB1 and CB2 protein levels were determined using
immunohistochemistry on samples, identified by a gynaecology
histopathologist as being representative of normal atrophic
endometrium, and of type 1 and type 2 EC. Staining was
performed using receptor-specific primary antibodies and
subsequent histomorphometric analyses. Briefly, formalin-
fixed sections of tissue were stained with CB1 (catalogue
number C1108) and CB2 (catalogue number C1358) antibodies
purchased from Sigma Life Science (Poole, Dorset, UK) and
used within standard immunohistochemistry (IHC) protocols,
with antibody amplification and 3,3’diaminobenzidine staining,
as described (16). Histomorphometric analyses were performed
using 10 randomised fields on each specimen with ImageScope
software (Aperio UK Ltd., Axbridge, Somerset, UK) to generate
an unbiased protein H-score, as described (16, 21–23). Specificity
controls for the technique were as described (16). Prior power
analysis for IHC studies (24) indicated that a minimum of six
specimen are required for any histomorphometric analyses.
Accordingly, we selected six atrophic, six each of grade 1, grade
2, and grade 3 type 1 EC and all four type 2 EC samples for
these studies.
Statistical Analysis
Statistical analysis was performed using Prism version 6:00 for
Windows (Graph-Pad Software, San Diego, CA; www.graphpad.
com). Demographic data are presented as mean ± SD and
data not following a Gaussian distribution are expressed as
median and interquartile ranges (IQR). Comparison between
groups was performed usingMann-WhitneyU-test. Correlations
were determined using Spearman correlation analysis. To
assess the diagnostic potential of each biomarker, receiver-
operating characteristic (ROC) curves were plotted and the areas
under curves (AUC) with 95% confidence intervals (95% CI),
sensitivity, and specificity values calculated. Logistic regression
was performed to indicate the probability of diagnosing EC using
the combinations of plasma AEA, PEA, and OEA concentrations.
Both ROC and logistic regression statistical analysis were
performed using MedCalc version 15.5 (Ostend, Belgium). A
p-value of <0.05 was considered statistically significant.
RESULTS
A total of 31 volunteers with cancer were studied: 27 had
type 1 endometrioid adenocarcinoma and four had type 2 EC
(two serous, one carcinosarcoma, and one clear cell carcinoma).
Among those with type 1 EC, 12 had grade 1, 11 had grade 2,
and four had grade 3 disease. In addition to tissue biopsies, only
15 patients with EC consented to provide plasma samples (12
with type 1 EC and 3 with type 2 EC). Seven volunteers with
an atrophic endometrium were recruited as controls; all of these
provided plasma samples.
Patient Characteristics
The mean (± SD) ages of the women studied were 60.7 ± 4.3
years for the controls (n = 7), 65.5 ± 10.2 years for type 1 EC
(n = 27) and 56.8 ± 7.9 for type 2 EC (n = 4). These were not
significantly different. Themean (± SD) BMI of 26.6± 5.9 kg/m2
for the controls was significantly (p< 0.05) lower than 34.8± 7.8
kg/m2 for type 1 EC and 38.0± 5.8 kg/m2 for type 2 EC patients.
There were no significant relationships between age or BMI with
either plasma or tissue NAE measurements (data not shown).
Plasma NAE Concentrations
Plasma AEA and PEA, but not OEA, concentrations (Table 1)
were significantly higher in patients with EC than in the controls
(p = 0.037, p = 0.0066, and p > 0.05, respectively). Plasma AEA
and PEA but not OEA concentrations in those with type 1 EC
were significantly higher than in the control group (p= 0.0129, p
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TABLE 1 | Plasma AEA, OEA, and PEA concentrations in EC and control patients.
Ligand Patient group
Control n = 7 EC (all patients)
n = 15
All Type 1 EC
n = 12
Type 1 EC G1
n = 6
Type 1 EC G2
n = 4
Type 1 EC G3
n = 2












































The data are presented as median (inter-quartile range) and plasma NAE concentrations are shown in nM. Significantly different comparisons; *p < 0.05; **p < 0.01;***p < 0.001; ****p
< 0.0001; n.s. not significantly different when compared to the control; Mann-Whitney U-test are indicated in bold font. Numbers of samples (n) are shown. G, tumour grade.
TABLE 2 | AEA, OEA, and PEA levels in the endometrial tissues of EC and control patients.
Ligand Patient group
Control n = 7 All EC n = 31 All Type 1 EC
n = 27
Type 1 EC G1
n = 12
Type 1 EC G2
n = 11
Type 1 EC G3
n = 4












































The data are presented as median (inter-quartile range). The values of NAE levels are shown as pmol/g of tissue. Significantly different comparisons; *p < 0.05; **p < 0.01;***p < 0.001;
****p < 0.0001; n.s. not significantly different when compared to the control; Mann-Whitney U-test are indicated in bold font. Numbers of samples (n) are shown. G, tumour grade.
= 0.0001, p> 0.05, respectively). In patients with type 2 EC, NAE
concentrations were similar to those of the controls.
Tissue NAE Levels
Tissue AEA and PEA, but not OEA, levels (Table 2) were
significantly higher in cancerous than in benign tissues (p =
0.046, p = 0.032, and p > 0.05, respectively). Type 1 EC
tissue contained significantly higher AEA, OEA, and PEA levels
compared to control (benign) tissues (p = 0.0159, p = 0.0263,
and p = 0.0015), respectively. PEA levels in type 2 EC tissues
were significantly lower (p = 0.0061) than in control (benign)
tissue, whilst the AEA and OEA levels were similar. Tissue OEA
levels of all grades (1, 2, and 3) of EC were similar to those of the
control endometrium, whereas those of AEA and PEA in grade 1
cancerous tissues were significantly higher (p = 0.0016 and p =
0.0002, respectively).
Correlations Between Plasma
Concentrations and Endometrial Tissue
Levels of AEA, OEA, and PEA
Having determined the levels of NAEs in plasma and tissues, the
next logical analysis was to determine if these two parameters
were related. Stratification into the three patient groups indicated
no significant group-specific correlations between any of the
tissue or plasma NAE measurements. However, when combined
into a single study cohort, there was a statistically significant
correlation between plasma and tissue AEA levels [R2 = 0.302,
p= 0.008; n= 22, (Figure 1A)] and plasma and tissue PEA levels
(R2 = 0.182, p= 0.048, n= 22) (Figure 1B). There was, however,
no statistically significant correlation between plasma and tissue
OEA levels (R2 = 0.022, p= 0.506, n= 22) (Figure 1C).
Correlations Between Endometrial Tissue
Levels of AEA, OEA, PEA, and CB1 or
CB2 Levels
We hypothesised that reduced expression of cannabinoid
receptor proteins (CB1 and/or CB2) might be related to the
observed increases in tissue AEA, OEA, and PEA levels. A
simple correlation analysis of H-score measurements of CB1
immunoreactivity indicated a significant inverse correlation
between tissue AEA levels and CB1 protein levels [R2 = 0.343,
p = 0.0003, n = 34 (Figure 2A)] and between tissue PEA
levels and CB2 protein levels [R2 = 0.384, p < 0.0001, n =
34, (Figure 2B)]. There was, however, no statistically significant
correlation between tissue OEA levels and CB1 protein levels (R2
= 0.003, p = 0.745, n = 34) (Figure 2C). Additionally, there
were no significant correlations between any of the tissue levels
of AEA, PEA or OEA, and CB2 protein levels (Figures 2D–F,
respectively). Stratification of these data into the three patient
groups indicated significant inverse correlations only between
CB1 expression and tissue AEA levels in the type 1 EC patients
(r = −0.607, p = 0.007); CB1 expression and tissue PEA
levels in type 1 EC patients (r = −0.719, p < 0.001) and a
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FIGURE 1 | Correlation curves showing the relationships between tissue
levels of AEA, PEA, and OEA with plasma concentrations. The relationships
between plasma concentrations and tissue levels (n = 22) of AEA (A), PEA
(B), and OEA (C) are shown. The indicated R2 and p-values were obtained
using Spearman correlation analysis.
positive correlation between CB1 expression and PEA levels in
type 2 EC patients (r = 0.676, p = 0.031). By contrast, only
significant correlations between CB2 expression and tissue AEA
(r = 0.746, p < 0.001) and PEA levels (r = 0.600, p = 0.008)
were demonstrated in type 1 EC patients. All other combinations
showed no significant associations.
Plasma Concentration ROC Curves
ROC curves were constructed for plasma NAEs from 22 (15
EC plus 7 control) patients (Figure 3). Plasma concentrations of
AEA had the best diagnostic accuracy for all types of EC with
an AUC of 0.781. At a cut-off value of 1.36 nM, the sensitivity
was 53.3% and specificity was 100% for the diagnosis of EC
(p = 0.0734) for a likelihood ratio of 5.25. When the ROC
analysis was applied to the diagnosis of type 1 EC only (n =
19; 12 EC and seven controls) the AUC increased to 0.845 for
a sensitivity of 66.7% and a specificity of 100% (p = 0.0246;
likelihood ratio 4.50).
The ROC for plasma PEA concentration (n = 22; 15 EC and
seven controls) revealed the best diagnostic accuracy for all types
of EC with an AUC of 0.857 (Figure 3). For a cut-off of 27.5 nM,
its sensitivity was 73.3% and the specificity was 100% (p< 0.0001;
likelihood ratio 6.07). Focussing only on type 1 EC (n = 19; 12
EC and seven controls), the plasma PEA cut-off value became
23.8 nM for the seven controls and 12 type 1 EC plasma PEA
samples. The AUC was 0.821 for the diagnosis of type 1 EC with
a sensitivity of 83.3% and a specificity of 85.7% (p = 0.0026;
likelihood ratio 5.83).
When plasmaOEA concentration wasmodelled for diagnostic
accuracy for all types of EC, an AUC of 0.543 was generated,
for a cut-off value of 4.965 nM, for a sensitivity of 93.3% and a
specificity of 28.6% (p > 0.05), with a likelihood ratio of 1.307.
When the modelling was confined to the diagnosis of type 1
EC only (n = 19), the AUC increased to 0.583 with an optimal
cut-off value of 6.655 nM, providing a sensitivity of 66.7% and a
specificity of 57.1% (p= 0.0026; likelihood ratio of 1.56).
When the plasma concentrations of AEA and PEA were
combined to generate ROC curves for the diagnosis of all types
of EC, the AUC increased from 0.781 for AEA and 0.857 for PEA
to 0.924. For type 1 EC alone, the AUC increased to 0.917. When
all the three NAEs (AEA, PEA, and OEA) were combined, the
AUC of the ROC curve for the diagnostic accuracy of all types
of EC increased from 0.781 for AEA, 0.857 for plasma PEA and
0.543 for plasma OEA to 0.933. When the analysis was repeated
but only for type 1 EC, a value similar to that obtained with
plasma concentrations of AEA and PEA combined but with OEA
omitted (0.917) was generated.
DISCUSSION
The levels of AEA and PEA were significantly higher in the
plasma and tissues of patients with EC when compared to
age-matched controls. The levels of these two NAEs were also
significantly inversely correlated with CB1 protein levels that
decrease in the endometrial cancer tissue, suggesting that loss of
this particular receptor results in increased availability of AEA
and PEA in the tissue and subsequently in plasma. These findings
suggest that these NAEs may be involved in the pathogenesis
of EC. These data are similar to those produced by Guida
et al. (25), in that both tissue AEA and PEA levels were
elevated in EC, but differed in their absolute measurements,
presumably because of differences in tissue selection (Guida
et al. describe contamination of tumour with normal tissue as
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FIGURE 2 | Correlation between tissue levels of AEA, PEA, and OEA with tissue protein expression levels. The relationships between tissue levels of AEA and CB1 or
CB2 protein (A,D), tissue levels of PEA and CB1 and CB2 protein (B,E) and OEA and CB1 or CB2 protein (C,F) are shown. The data for atrophic controls (n = 6) are
shown by filled circles and those for the EC patients (n = 28; 24 Type 1 and 4 type 2 EC) by open circles. The indicated R2 and p-values were obtained using Pearson
correlation analysis.
being an issue in their study). Guida et al., also reported loss
of CB1 receptor protein, but did not relate the tissue AEA and
PEA levels to changes in receptor expression. Previous studies
have demonstrated that the levels of the endocannabinoid 2-
AG were significantly increased in endometrial (25) and other
cancers (14, 26), suggesting that other endocannabinoids might
be elevated in EC. An important observation in the present study
was the positive correlation between plasma concentrations and
tissue levels of AEA and PEA, something that, to our knowledge,
has not been reported previously, even in the 2-AG study (25).
This significant positive correlation between plasma AEA and
PEA concentrations with tissue levels, but not that of OEA, led us
to hypothesise that plasma levels of the former are surrogates of
tissue levels and that these could be used as markers for diagnosis.
An alternative hypothesis that the NAEs are produced in other
parts of the body and accumulate in the rapidly metabolising
tumour tissue is not supported because (1) there should be
a strong correlation between the plasma concentrations of all
three NAEs and tissue NAEs if this was the only determinant
(and there was not a strong correlation for OEA) and (2) as
blood volume increases then tissue concentration should also
increase (this was not observed in our cohort). Examination
of correlates between BMI (a measurement of patient size
and blood volume), which is known to increase EC risk in
our patients (27) and tissue NAE concentrations, indicated
there was no relationship between these parameters in any
of the patient groups. Since the endometrium expresses the
enzymes that regulate the tissue and plasma concentrations
of these (28) and other endocannabinoids (25), then it is
highly likely that plasma NAE concentrations are a reflection of
the balance between direct NAE synthesis and degradation in
the endometrium.
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FIGURE 3 | ROC analyses for AEA and PEA. The upper panels show the ROC analyses for AEA (Left) and PEA (Right) for the diagnosis of EC, using a cut-off
plasma concentration of 1.36 nM for AEA and 27.5 nM for PEA. The data also show the sensitivity and specificity values for these biomarkers together with the value
for the area under the ROC curve and their 95% confidence intervals (CI). The lower panels show similar analyses, but for the comparison of EC grade 1 tumour
patients only compared to the controls. In this case, the cut-off plasma concentration remained at 1.36 nM for AEA and changed to 23.8 nM for PEA.
The ROC analyses in the present study were designed
to identify the possible cut-off values for the plasma NAE
concentrations and thus provide support to the notion that
these plasma biomarkers could have the potential to be used
as clinical biomarkers in the future. We have thus performed
the “detection” stage of ROC analysis for the NAEs as plasma
biomarkers; the “validation” stage will need to be performed in
a double blind randomised clinical trial based on the plasma
cut-off values and predictability values presented herein. The
specificity and sensitivity of plasmaAEA and PEA concentrations
in discriminating between patients with benign endometria and
those with EC appear to be superior to other serum biomarkers
that have been published, such as encapsulated miRNA species,
cyclophilin A and HE-4 (29), as evidenced by logistic regression
analysis. The latter shows that the combination of these ligands
(AEA and PEA) gives a better detection (AUC of 0.933) than
either NAE alone. Previously reported serummarkers of EC, such
as CA125 and CA15-3 only produced 11–34 and 47% specificity
values for advanced stage tumours, respectively (7), suggesting
that other markers or combinations would be useful. Indeed, the
addition of HE-4 to the analysis of CA-125 (30) produced a 12.9%
increase in accuracy for the diagnosis of early (type 1) EC, and
L1CAM when added to mutant p53 increased the probability of
detecting more advanced EC (31). This background prompted
us to combine AEA, PEA, and OEA data. The fact that there
was no significant change in plasma OEA concentrations or
correlation with tissue levels, suggests that this NAE is not
useful as a biomarker either alone or in combination with AEA
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and PEA, but may point towards a possible mechanism in EC
pathogenesis. The “entourage effect” is a well-known, but poorly
characterised phenomenon in endocannabinoid biology (32),
whereby the NAE degradative enzyme fatty acid amide hydrolase
(FAAH) preferentially degrades one of the substrates, whilst
sparing one or more others (33, 34). In the malignant tissue of
the endometrium, it appears that OEA is the preferential target of
endometrial FAAH, which might explain the lack of correlation
between plasma concentrations and tissue OEA levels (Figure 1),
and the lack of difference between plasma concentrations and
tissue levels in the EC patients (Tables 1, 2). This hypothesis will
need to be tested further, but is highly likely, based on current
observations, that the levels and function of FAAH will also be
altered in EC, as they are in other tumours (35, 36).
An alternative hypothesis relates to dysregulation of the
endocannabinoid system by sex steroid hormones. The observed
higher AEA and PEA levels in the tissue (and thus in the plasma)
might be due to an imbalance in the estrogen to progesterone
ratio, a known factor involved in the development of EC.
This was elegantly demonstrated in a mouse study (37), where
endocannabinoid synthesis was found to be directly regulated by
estradiol. Furthermore, AEA plasma concentrations have been
demonstrated to directly correlate with human endocannabinoid
biosynthesis in response to estrogen, but not progesterone (38).
In addition, estrogen reduces (39) and progesterone increases
(40) human FAAH activity and expression, which correlates with
observed AEA and PEA tissue levels and the endometrioid nature
of the type 1 EC highlighted in the present study (41, 42).
The outcomes of these changes are difficult to predict in vivo,
but increased mitotic activity and enhanced DNA replication in
endometrial cells caused by an aberrant estrogen to progesterone
ratio (43)may also affect the expression of cannabinoid receptors,
as has been reported by Guida et al. (25). A role for estrogens in
the pathogenesis of type 1 EC through the production of NAEs
is supported by the observation that AEA and PEA were not
elevated in type 2 EC, which is known to be less responsive to
endogenous and exogenous estrogens (44). The reduction of PEA
in the endometrium of patients with type 2 EC, suggest different
pathogenic pathways involved in type 2 EC that are distinct to
that of type 1 EC where PEA levels increase. Whether this is a
cause or effect is something that needs further investigations.
NAEs are increasingly being recognised to play multiple roles
in the regulation of key processes involved in the development of
cancer. For example, they are reported to induce apoptosis (45,
46), cell cycle arrest (47, 48), and the inhibition of angiogenesis
and metastasis (49). Furthermore, endocannabinoid signalling in
malignant cells may differ to that of their “normal” counterpart
(50). These data suggest that NAEs are not only potentially useful
for the diagnosis of EC, but that factors that control the synthesis
and degradation of these lipids, or their activation of receptor
expression, could be key to an effective non-invasive treatment,
as has been proposed for other cancers (8, 50).
Although the number of patients recruited to the present
study may be considered a limitation, our number of those with
EC type 1 is similar to that of Guida et al. (25) hence our results
are thus supportive of AEA and PEA being intimately involved
in the pathogenesis of EC type 1. The number of EC type 2
patients was smaller than for EC type 1, which is a reflection on
the prevalence of the two types of EC in the UK population (44),
but such data could provide the basis for further research, which
would be important so as to substantiate the present findings. For
example, the significance of the data presented here suggest that
plasmaNAEs and of other endocannabinoids (8, 15) will be useful
in the diagnosis and possible management of EC patients, and
may have both pathophysiological and diagnostic consequences
for EC.
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